As the second largest pharmaceutical R & D service platform in China and one of the three major drug discovery service providers in the world, Pharmaron Beijing Co.Ltd(300759) ( Pharmaron Beijing Co.Ltd(300759) ) continued its performance growth trend in 2021 and plans to launch high delivery. At the same time, the company continues to expand the pace of M & A, and plans to acquire 100% equity of Beijing Ankai Yibo Biotechnology Co., Ltd. (hereinafter referred to as “Ankai Yibo”) to strengthen the quality control of experimental animals.
plans to transfer RMB 4.5 from 10 to 5
Pharmaron Beijing Co.Ltd(300759) , who landed in the capital market in 2019, is mainly engaged in drug research, development and production services. The company’s business is closely related to the development of the pharmaceutical industry and drug R & D outsourcing market.
On March 27, the company disclosed that the annual report of 2021 showed that during the period, the company realized an operating revenue of 7.444 billion yuan, an increase of 45% over the same period last year (if calculated according to the exchange rate of the same period last year, the operating revenue increased by 52.25% over the same period last year); With the increase of income, the scale effect of profit was further enhanced, and the operating profit was 1.914 billion yuan; The gross profit margin of main business reached 36.02%, a decrease of 1.38 percentage points over last year (if calculated according to the exchange rate of the same period last year, the gross profit margin of main business was 38.76%, an increase of 1.36 percentage points over last year); The net profit was 1.661 billion yuan, an increase of 41.68% over the same period last year; The non net profit deducted was 1.341 billion yuan, an increase of 67.46% over the same period last year.
In 2021, Pharmaron Beijing Co.Ltd(300759) plans to carry out high transfer. The announcement shows that the profit distribution plan reviewed and approved by the board of directors is to distribute cash dividends of 4.5 yuan (including tax) for every 10 shares to all shareholders based on 794 million shares, and increase 5 shares for every 10 shares to all shareholders with capital reserve. Previously, in 2020, the company also implemented a cash dividend of 3 yuan (including tax) for every 10 shares.
Pharmaron Beijing Co.Ltd(300759) said that the company’s business can be divided into four service sectors according to the main business types: laboratory services, CMC (small molecule cdmo) services, clinical research services, macromolecules and cell and gene therapy services. Among them, in 2021, the company’s laboratory service revenue increased rapidly, realizing an operating revenue of 4.566 billion yuan, an increase of 41.09% over the same period of the previous year, and realizing a gross profit margin of 43.47%, an increase of 0.7 percentage points over the same period of the previous year; CMC (small molecule cdmo) service achieved an operating revenue of 1.746 billion yuan, an increase of 42.9% over the same period last year, and achieved a gross profit margin of 34.92%, an increase of 2.2 percentage points over the same period last year.
In addition, Pharmaron Beijing Co.Ltd(300759) about 90% of the revenue comes from the top 20 pharmaceutical enterprises in the world, among which the revenue from customers from the top 20 pharmaceutical enterprises accounts for 18.97% of the company’s operating revenue.
The company said it had introduced more than 800 new customers in 2021. In 2021, revenue from customers in North America accounted for 64.2%, revenue from customers in Europe (including the UK) accounted for 15.63%, revenue from customers in China accounted for 17.13%, and revenue from customers in other regions accounted for 3.04%. With the increasing number of customers of the company, the revenue concentration of the top 20 customers further decreased from 41.06% in 2020 to 33.75% in 2021, and the revenue structure continued to be optimized.
acquisition of 100% equity of Ankai Yibo
In order to build the strategy of full process and integrated service platform, Pharmaron Beijing Co.Ltd(300759) in recent years, through internal construction and extension mergers and acquisitions, while increasing production capacity to meet the growth needs of existing business, it has further improved the company’s international service platform and focused on the development of new business. In 2021, the company’s capital expenditure for internal construction and extension M & A was 2.093 billion yuan and 1.437 billion yuan respectively, an increase of 59.05% and 30.61% respectively compared with 2020.
On March 27, Pharmaron Beijing Co.Ltd(300759) announced that it planned to acquire 100% equity of Ankai Yibo held by Chen Jing and Chen Xuejun with its own funds.
Chen Jing is the actual controller, chairman and CEO of Pharmaron Beijing Co.Ltd(300759) , and also the spouse of Lou Guoqiang, the brother of Lou Xiaoqiang, the actual controller, director and chief operating officer of the company. She holds 75% equity of Ankai Yibo.
It is disclosed that Ankai Yibo’s main business is to raise and reproduce experimental animals (SPF Rats and mice without specific disease source) (the production license of experimental animals is valid until December 28, 2022). The value of all shareholders’ equity obtained by the income method in this acquisition appraisal is 83.6 million yuan, the book value is 142083 million yuan, the appraisal value-added is 693918 million yuan, and the appreciation rate reaches 488.39%.
Pharmaron Beijing Co.Ltd(300759) said that this transaction is conducive to further strengthening the company’s quality control of experimental animals, optimizing the company’s experimental animal supply system and strengthening the company’s ability in biosciences such as drug safety evaluation. The funds required for this transaction are the company’s own funds, which will not have a significant adverse impact on the company’s financial and operating conditions, and there is no situation that damages the interests of listed companies and minority shareholders. However, after the completion of this transaction, the company may face relevant risks such as operation, management and subsequent integration in the business process. The company will actively take effective measures and Countermeasures to control and resolve the risks.
